Continuing Education Activity
ACCC 37th National Oncology Conference [On-Demand]Contains 11 Product(s)
The leading conference for innovation in cancer care delivery is now available on-demand! Participation in the enduring activities of the ACCC 37th [Virtual] National Oncology Conference will be available for 12 months and will award continuing education hours for physicians, nurses, pharmacists, and administrators as appropriate.
Emerging Therapies for the Management of Castration - Sensitive Prostate CancerContains 5 Component(s), Includes Credits
Component Credit Type State/Medical Type Available Credits Earned Credits CME/CPE/CNE/Certificate of Participation Medical CME 1.00 0.00 CME/CPE/CNE/Certificate of Participation Medical CPE 1.00 0.00 CME/CPE/CNE/Certificate of Participation Medical CNE 1.00 0.00 CME/CPE/CNE/Certificate of Participation Medical Certificate of Participation 1.00 0.00
With recent drug approvals and updates to clinical practice guidelines, many oncology practitioners find it challenging to stay abreast of changing treatment recommendations for patients with mCSPC (metastatic castration-sensitive prostate cancer). This activity aims to provide guidance on the latest in optimal management of mCSPC for oncologists, urologists, oncology advanced practitioners and other members of the multidisciplinary cancer care team. The course will address challenges in optimal sequencing of care in mCSPC and will provide learners an opportunity to hear from experts regarding new research and clinical updates that can be translated into patient care strategies.
Optimizing Outcomes for Patients with Urothelial Carcinoma: Recent Clinical UpdatesContains 5 Component(s), Includes Credits
Component Credit Type State/Medical Type Available Credits Earned Credits CME/CNE/Certificate of Participation Medical CME 0.75 0.00 CME/CNE/Certificate of Participation Medical CNE 0.75 0.00 CME/CNE/Certificate of Participation Medical Certificate of Participation 0.75 0.00
In a recent survey of community cancer care professionals conducted by the Association of Community Cancer Centers, bladder was reported to be one of the most commonly diagnosed cancers after breast, lung, prostate, and colorectal. For many community oncologists, it is hard to stay abreast of clinical updates and changing treatment recommendations across all tumor types. This initiative will summarize recent clinical data for immunotherapies and emerging targeted therapies used to treat advanced and metastatic urothelial carcinoma. Strategies for identification and management of treatment-related adverse events, as well as effective solutions for improving multidisciplinary care coordination, will also be covered.
Oral Agents for Advanced Hormone Receptor Positive Breast CancerContains 5 Component(s), Includes Credits
Component Credit Type State/Medical Type Available Credits Earned Credits CME/CNE/Certificate of Participation Medical CME 1.00 0.00 CME/CNE/Certificate of Participation Medical CNE 1.00 0.00 CME/CNE/Certificate of Participation Medical Certificate of Participation 1.00 0.00
A 3-member faculty panel will discuss treatment decisions for clinical case scenarios in advanced HR+ breast cancer. The panel will discuss challenging cases of patients and will offer guidance on evidence-based treatment choices for patients in the various lines of treatment and for managing treatment-related severe adverse events in these patients.
|Access Date||Quiz Result||Score||Actions|